Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease
Mudasir Maqbool, Mohammad Mobashir, Nasimul Hoda
European Journal of Medicinal Chemistry (2015) Vol. 107, pp. 63-81
Closed Access | Times Cited: 220

Showing 1-25 of 220 citing articles:

Alzheimer's disease: Recent treatment strategies
Miguel Vaz, Samuel Silvestre
European Journal of Pharmacology (2020) Vol. 887, pp. 173554-173554
Closed Access | Times Cited: 438
A walk through tau therapeutic strategies
Santosh Jadhav, Jesús Ávila, Michael Schöll, et al.
Acta Neuropathologica Communications (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 248
BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease
Nour M. Moussa‐Pacha, Shifaa M. Abdin, Hany A. Omar, et al.
Medicinal Research Reviews (2019) Vol. 40, Iss. 1, pp. 339-384
Open Access | Times Cited: 245
Dynamics of diabetes and obesity: Epidemiological perspective
Annette Boles, Ramesh Kandimalla, P. Hemachandra Reddy
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2017) Vol. 1863, Iss. 5, pp. 1026-1036
Open Access | Times Cited: 241
Restoring Wnt/β-catenin signaling is a promising therapeutic strategy for Alzheimer’s disease
Lin Jia, Juan C. Piña‐Crespo, Yonghe Li
Molecular Brain (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 226
Memantine for the Treatment of Dementia: A Review on its Current and Future Applications
Jaume Folch, Oriol Busquets, Miren Ettcheto, et al.
Journal of Alzheimer s Disease (2017) Vol. 62, Iss. 3, pp. 1223-1240
Open Access | Times Cited: 203
Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease
Teeba Athar, Khalid Al Balushi, Shah Alam Khan
Molecular Biology Reports (2021) Vol. 48, Iss. 7, pp. 5629-5645
Open Access | Times Cited: 183
Neuroinflammation and Neurogenesis in Alzheimer’s Disease and Potential Therapeutic Approaches
Pi‐Shan Sung, Po‐Yu Lin, Chi‐Hung Liu, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 3, pp. 701-701
Open Access | Times Cited: 154
Glycogen synthesis and beyond, a comprehensive review of GSK3 as a key regulator of metabolic pathways and a therapeutic target for treating metabolic diseases
Li Wang, Jiajia Li, Li‐jun Di
Medicinal Research Reviews (2021) Vol. 42, Iss. 2, pp. 946-982
Open Access | Times Cited: 124
Potential and Therapeutic Roles of Diosmin in Human Diseases
Etimad Huwait, Mohammad Mobashir
Biomedicines (2022) Vol. 10, Iss. 5, pp. 1076-1076
Open Access | Times Cited: 88
More than a marker: potential pathogenic functions of MAP2
Rebecca A. DeGiosio, Melanie Grubisha, Matthew L. MacDonald, et al.
Frontiers in Molecular Neuroscience (2022) Vol. 15
Open Access | Times Cited: 84
Nrf2 activation in the treatment of neurodegenerative diseases: a focus on its role in mitochondrial bioenergetics and function
Noemí Esteras, Albena T. Dinkova‐Kostova, Andrey Y. Abramov
Biological Chemistry (2016) Vol. 397, Iss. 5, pp. 383-400
Open Access | Times Cited: 150
Neuroprotective Functions for the Histone Deacetylase SIRT6
Shai Kaluski, Miguel Portillo, B Antoine, et al.
Cell Reports (2017) Vol. 18, Iss. 13, pp. 3052-3062
Open Access | Times Cited: 147
Multiple faces of dynamin-related protein 1 and its role in Alzheimer's disease pathogenesis
Ramesh Kandimalla, P. Hemachandra Reddy
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2015) Vol. 1862, Iss. 4, pp. 814-828
Open Access | Times Cited: 131
MiR-124-3p attenuates hyperphosphorylation of tau protein-induced apoptosis via caveolin-1-PI3K/Akt/GSK3β pathway in N2a/APP695swe cells
Qingmei Kang, Yue Xiang, Dan Li, et al.
Oncotarget (2017) Vol. 8, Iss. 15, pp. 24314-24326
Open Access | Times Cited: 109
Targeting GSK3 signaling as a potential therapy of neurodegenerative diseases and aging
Przemysław Duda, J. Wisniewski, Tomasz Wójtowicz, et al.
Expert Opinion on Therapeutic Targets (2018) Vol. 22, Iss. 10, pp. 833-848
Closed Access | Times Cited: 109
β-amyloid redirects norepinephrine signaling to activate the pathogenic GSK3β/tau cascade
Fang Zhang, Mary Gannon, Yunjia Chen, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 526
Open Access | Times Cited: 108
Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions
A. Prasanth Saraswati, S.M. Ali Hussaini, Namballa Hari Krishna, et al.
European Journal of Medicinal Chemistry (2017) Vol. 144, pp. 843-858
Closed Access | Times Cited: 105
Neuroprotective role of astaxanthin in hippocampal insulin resistance induced by Aβ peptides in animal model of Alzheimer’s disease
Syed Obaidur Rahman, Bibhu Prasad Panda, Suhel Parvez, et al.
Biomedicine & Pharmacotherapy (2018) Vol. 110, pp. 47-58
Open Access | Times Cited: 105
Integrating Highly Efficient Recognition and Signal Transition of g-C3N4 Embellished Ti3C2 MXene Hybrid Nanosheets for Electrogenerated Chemiluminescence Analysis of Protein Kinase Activity
Yan Sun, Yimeng Zhang, Huixin Zhang, et al.
Analytical Chemistry (2020) Vol. 92, Iss. 15, pp. 10668-10676
Closed Access | Times Cited: 93
Dual GSK-3β/AChE Inhibitors as a New Strategy for Multitargeting Anti-Alzheimer’s Disease Drug Discovery
Xueyang Jiang, Tingkai Chen, Junting Zhou, et al.
ACS Medicinal Chemistry Letters (2018) Vol. 9, Iss. 3, pp. 171-176
Open Access | Times Cited: 92
Developments with multi-target drugs for Alzheimer’s disease: an overview of the current discovery approaches
Juan F. González, Andrés R. Alcántara, A. Doadrio, et al.
Expert Opinion on Drug Discovery (2019) Vol. 14, Iss. 9, pp. 879-891
Closed Access | Times Cited: 81
The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer’s disease in rodents
Guy Griebel, Jeanne Stemmelin, Mati Lopez‐Grancha, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 79
Discovery of Novel Tacrine–Pyrimidone Hybrids as Potent Dual AChE/GSK-3 Inhibitors for the Treatment of Alzheimer’s Disease
Hong Yao, Giuseppe Uras, Pengfei Zhang, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 11, pp. 7483-7506
Open Access | Times Cited: 58
Circadian clocks, cognition, and Alzheimer’s disease: synaptic mechanisms, signaling effectors, and chronotherapeutics
Kari R. Hoyt, Karl Obrietan
Molecular Neurodegeneration (2022) Vol. 17, Iss. 1
Open Access | Times Cited: 39
Page 1 - Next Page

Scroll to top